MENU
Showcases Stock ranks Forex

Karuna Therapeutics Inc (KRTX)
241.19  100.83 (71.84%) 08-08 16:00
Open: 220.92 Pre. Close: 140.36
High: 245 Low: 212.31
Volume: 4,353,407 Market Cap: 7,207M
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of dementia-related psychosis. The company also focuses on developing other muscarinic-targeted drug candidates. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co., Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.
Prices Prediction (Update @5:00pm)
If tomorrow: Open lower Open higher
High: 245.147 - 245.872 245.872 - 246.683
Low: 210.35 - 211.138 211.138 - 212.019
Close: 239.63 - 240.965 240.965 - 242.461
Stock Technical Analysis
Overall:     
Target: Six months: 286.16
One year: 334.23
Support: Support1: 169.35
Support2: 122.59
Resistance: Resistance1: 245.00
Resistance2: 286.16
Pivot: 137.62
Moving Averages: MA(5): 153.66
MA(20): 135.90
MA(100): 120.66
MA(250): 120.33
MACD: MACD(12,26): 11.33
Signal(12,26,9): 4.46
%K %D: %K(14,3): 89.88
%D(3): 68.73
RSI: RSI(14): 88.54
52-Week: High: 245
Low: 92.26
Change(%): 130.0
Average Vol(K): 3-Month: 379
10-Days: 704
Price, MAs and Bollinger Bands
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.

[ KRTX ] has closed above the upper band by 42.6%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 342.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
Stock chart
Stock News
Mon, 08 Aug 2022
U.S. stocks mixed at close of trade; Dow Jones Industrial Average up 0.09% By Investing.com - Investing.com

Mon, 08 Aug 2022
Healthcare Stocks Making Moves Monday: KRTX, HSCS, CINC, SRGA, RETA, QURE, AXDX, GTHX - InvestorsObserver

Mon, 08 Aug 2022
Health Care Sector Update for 08/08/2022: BNTX, KRTX, SGFY, CVS - Nasdaq

Mon, 08 Aug 2022
Karuna's stock jumps 42% after sharing promising Phase 3 data for its schizophrenia drug - MarketWatch

Mon, 08 Aug 2022
Karuna Therapeutics Inc. Misses Q2 EPS by 11c By Investing.com - Investing.com India

Mon, 08 Aug 2022
Zai Lab Partner Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-2 Trial of KarXT in Schizophrenia - StreetInsider.com

Financial Analysis
Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Exchange:  NASDAQ Global Market
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 29.62
Shares Float (M) 23.02
% Held by Insiders 7.05
% Held by Institutions 100.35
Shares Short (K) 1420
Shares Short Prior Month (K) 1190
Stock Financials
EPS -4.920
Book Value (p.s.) 17.510
Profit Margin
Operating Margin -465.56
Return on Assets (ttm) -20.1
Return on Equity (ttm) -33.0
Qtrly Rev. Growth
Gross Profit (p.s.) 1.248
Sales Per Share 1.248
EBITDA (p.s.) -5.788
Qtrly Earnings Growth
Operating Cash Flow (M) -129.50
Levered Free Cash Flow (M) -70.11
Stock Valuation
PE Ratio -49.02
PEG Ratio 0.89
Price to Book value 13.77
Price to Sales 193.29
Price to Cash Flow -55.17
Stock Dividends
Dividend
Dividend Yield
Dividend Growth

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android